Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Published: 06 Nov 2022

  • Views:

    Views Icon 465
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 22 - Dr Gurleen Kaur (Brigham and Women's Hospital, US) joins us in this collaboration between @CardioNerds and Radcliffe Cardiology to interview OCEAN(a)'s primary investigator, Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) on the late-breaking data revealed at AHA. 

OCEAN(a) was a dose-finding study that aimed to evaluate an siRNA, olpasiran's (Amgen) effect administered subcutaneously compared with placebo on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease and elevated Lipoprotein(a) (NCT05581303).

The trial showed that, dosed 75 mg or higher every 12 weeks, olpasiran reduces Lp(a) concentration by more than 95% in patients with atherosclerotic cardiovascular disease. The phase 2 study demonstrated that the treatment appears to be safe and well-tolerated.

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Boston, 2022

Editors: Jordan Rance and Mirjam Boros
Video Specialists: Dan Brent and Oliver Miles